• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过血浆 IG 蛋白质组学和单个 B 细胞 IG 测序定义的抗疟抗体库。

Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing.

机构信息

Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.

University Children's Hospital Zurich, Zurich, Switzerland.

出版信息

JCI Insight. 2020 Nov 19;5(22):143471. doi: 10.1172/jci.insight.143471.

DOI:10.1172/jci.insight.143471
PMID:33048842
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7710313/
Abstract

Plasma antimalarial Ab can mediate antiparasite immunity but has not previously been characterized at the molecular level. Here, we develop an innovative strategy to characterize humoral responses by integrating profiles of plasma immunoglobulins (IGs) or Abs with those expressed on B cells as part of the B cell receptor. We applied this strategy to define plasma IG and to determine variable (V) gene usage after vaccination with the Plasmodium falciparum zygote antigen Pfs25. Using proteomic tools coupled with bulk immunosequencing data, we determined human antigen-binding fragment [F(ab')2] peptide sequences from plasma IG of adults who received 4 doses of Pfs25-EPA/Alhydrogel. Specifically, Pfs25 antigen-specific F(ab')2 peptides (Pfs25-IG) were aligned to cDNA sequences of IG heavy (IGH) chain complementarity determining region 3 from a data set generated by total peripheral B cell immunosequencing of the entire vaccinated population. IGHV4 was the most commonly identified IGHV subgroup of Pfs25-IG, a pattern that was corroborated by V heavy/V light chain sequencing of Pfs25-specific single B cells from 5 vaccinees and by matching plasma Pfs25-IG peptides and V-(D)-J sequences of Pfs25-specific single B cells from the same donor. Among 13 recombinant human mAbs generated from IG sequences of Pfs25-specific single B cells, a single IGHV4 mAb displayed strong neutralizing activity, reducing the number of P. falciparum oocysts in infected mosquitoes by more than 80% at 100 μg/mL. Our approach characterizes the human plasma Ab repertoire in response to the Pfs25-EPA/Alhydrogel vaccine and will be useful for studying circulating Abs in response to other vaccines as well as those induced during infections or autoimmune disorders.

摘要

血浆抗疟抗体可介导抗寄生虫免疫,但以前尚未在分子水平上进行表征。在这里,我们开发了一种创新策略,通过整合血浆免疫球蛋白(IG)或抗体的图谱与作为 B 细胞受体一部分表达的 B 细胞上的图谱来表征体液反应。我们应用该策略来定义血浆 IG,并确定接种恶性疟原虫合子抗原 Pfs25 后 V 基因的使用情况。使用与批量免疫测序数据相结合的蛋白质组学工具,我们从接受了 4 剂 Pfs25-EPA/Alhydrogel 的成年人的血浆 IG 中确定了人类抗原结合片段[F(ab')2]肽序列。具体来说,将 Pfs25 抗原特异性 F(ab')2 肽(Pfs25-IG)与来自整个接种人群外周血 B 细胞免疫测序数据集的 IG 重链互补决定区 3 的 cDNA 序列进行比对。IGHV4 是 Pfs25-IG 最常见的鉴定 IGHV 亚组,这一模式得到了来自 5 名疫苗接种者的 Pfs25 特异性单 B 细胞的 V 重链/V 轻链测序以及来自同一供体的 Pfs25 特异性单 B 细胞的血浆 Pfs25-IG 肽和 V-(D)-J 序列的证实。在从 Pfs25 特异性单 B 细胞的 IG 序列中产生的 13 种重组人单克隆抗体中,一种 IGHV4 单克隆抗体表现出很强的中和活性,在 100μg/ml 时使感染蚊子中的恶性疟原虫卵囊数量减少了 80%以上。我们的方法对 Pfs25-EPA/Alhydrogel 疫苗的人类血浆 Ab 库进行了特征描述,这将有助于研究针对其他疫苗以及感染或自身免疫性疾病期间诱导的循环 Abs。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/5a406d3e1d30/jciinsight-5-143471-g170.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/5625891fc76f/jciinsight-5-143471-g164.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/ef7fdef6a6d7/jciinsight-5-143471-g165.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/2500464e0a44/jciinsight-5-143471-g166.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/d1f36f5910a2/jciinsight-5-143471-g167.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/940afe7dad49/jciinsight-5-143471-g168.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/bbb32e3ce817/jciinsight-5-143471-g169.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/5a406d3e1d30/jciinsight-5-143471-g170.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/5625891fc76f/jciinsight-5-143471-g164.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/ef7fdef6a6d7/jciinsight-5-143471-g165.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/2500464e0a44/jciinsight-5-143471-g166.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/d1f36f5910a2/jciinsight-5-143471-g167.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/940afe7dad49/jciinsight-5-143471-g168.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/bbb32e3ce817/jciinsight-5-143471-g169.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5fe/7710313/5a406d3e1d30/jciinsight-5-143471-g170.jpg

相似文献

1
Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing.通过血浆 IG 蛋白质组学和单个 B 细胞 IG 测序定义的抗疟抗体库。
JCI Insight. 2020 Nov 19;5(22):143471. doi: 10.1172/jci.insight.143471.
2
Poor CD4 T Cell Immunogenicity Limits Humoral Immunity to Transmission-Blocking Candidate Pfs25 in Humans.CD4 T 细胞免疫原性差限制了对人类传播阻断候选 Pfs25 的体液免疫。
Front Immunol. 2021 Sep 30;12:732667. doi: 10.3389/fimmu.2021.732667. eCollection 2021.
3
Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.用一种疟疾传播阻断候选疫苗Pfs25进行鼻腔免疫,可在小鼠中诱导出针对恶性疟原虫野外分离株的完全保护性免疫。
Infect Immun. 2005 Nov;73(11):7375-80. doi: 10.1128/IAI.73.11.7375-7380.2005.
4
Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.在人体中,Pfs230比Pfs25产生更高的疟疾传播阻断疫苗活性,但在小鼠中并非如此。
J Clin Invest. 2021 Apr 1;131(7). doi: 10.1172/JCI146221.
5
Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.佐剂和载体蛋白依赖性 T 细胞启动可促进针对恶性疟原虫 Pf25 疫苗候选物的强烈抗体反应。
Sci Rep. 2017 Jan 16;7:40312. doi: 10.1038/srep40312.
6
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.Pfs25-EPA/Alhydrogel®(一种针对恶性疟原虫的传播阻断疫苗)的安全性和免疫原性:一项针对未感染疟疾成年人的开放标签研究。
PLoS One. 2016 Oct 17;11(10):e0163144. doi: 10.1371/journal.pone.0163144. eCollection 2016.
7
Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.通过将Pfs25与IMX313多聚化技术融合来增强疟疾疫苗的免疫原性和传播阻断活性。
Sci Rep. 2016 Jan 8;6:18848. doi: 10.1038/srep18848.
8
Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.植物源 Pf s25 病毒样颗粒作为疟疾传播阻断疫苗的安全性和免疫原性:健康成年人中进行的 1 期剂量递增研究。
Vaccine. 2018 Sep 18;36(39):5865-5871. doi: 10.1016/j.vaccine.2018.08.033. Epub 2018 Aug 17.
9
Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.疟疾候选疫苗Pfs25/Pvs25诱导的传播阻断活性是抗体滴度的直接且可预测的函数。
Malar J. 2007 Aug 8;6:107. doi: 10.1186/1475-2875-6-107.
10
Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.评价针对疟原虫和 vivax 疟原虫传播的联合疫苗。
Vaccine. 2024 Aug 30;42(21):126140. doi: 10.1016/j.vaccine.2024.07.041. Epub 2024 Jul 20.

引用本文的文献

1
Public antibodies: convergent signatures in human humoral immunity against pathogens.公共抗体:人类针对病原体的体液免疫中的趋同特征
mBio. 2025 May 14;16(5):e0224724. doi: 10.1128/mbio.02247-24. Epub 2025 Apr 16.
2
Antibody gene features associated with binding and functional activity in malaria vaccine-derived human mAbs.疟疾疫苗衍生的人源单克隆抗体中与结合及功能活性相关的抗体基因特征。
NPJ Vaccines. 2024 Aug 10;9(1):144. doi: 10.1038/s41541-024-00929-6.
3
A human antibody epitope map of the malaria vaccine antigen Pfs25.疟疾疫苗抗原Pfs25的人源抗体表位图谱。

本文引用的文献

1
Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants.母体广谱中和抗体可选择对中和具有抗性的、能在婴儿中传播/形成的 HIV 变异株。
mBio. 2020 Mar 10;11(2):e00176-20. doi: 10.1128/mBio.00176-20.
2
Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine.人体对黄热病 17D 疫苗的 B 细胞反应的纵向动力学。
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6675-6685. doi: 10.1073/pnas.1921388117. Epub 2020 Mar 9.
3
Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies.
NPJ Vaccines. 2023 Aug 4;8(1):108. doi: 10.1038/s41541-023-00712-z.
4
Template-Based Assembly of Proteomic Short Reads For Antibody Sequencing and Repertoire Profiling.基于模板的蛋白质组学短读段组装,用于抗体测序和库特征分析。
Anal Chem. 2022 Jul 26;94(29):10391-10399. doi: 10.1021/acs.analchem.2c01300. Epub 2022 Jul 14.
5
Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2.通过增加 V2 上的 Ab-Ag 界面提高对多种 HIV-1 的中和广度。
Adv Sci (Weinh). 2022 May;9(15):e2200063. doi: 10.1002/advs.202200063. Epub 2022 Mar 23.
6
An Immunoproteomic Survey of the Antibody Landscape: Insights and Opportunities Revealed by Serological Repertoire Profiling.免疫蛋白质组学调查抗体全景:血清免疫球蛋白文库分析揭示的见解和机遇
Front Immunol. 2022 Feb 1;13:832533. doi: 10.3389/fimmu.2022.832533. eCollection 2022.
7
B cell clonal expansion and mutation in the immunoglobulin heavy chain variable domain in response to Pfs230 and Pfs25 malaria vaccines.针对 PfS230 和 PfS25 疟疾疫苗,免疫球蛋白重链可变区 B 细胞克隆扩增和突变。
Int J Parasitol. 2022 Oct;52(11):707-710. doi: 10.1016/j.ijpara.2021.11.008. Epub 2021 Dec 9.
8
Immunoglobulins or Antibodies: IMGT Bridging Genes, Structures and Functions.免疫球蛋白或抗体:国际免疫基因组学数据库(IMGT)连接基因、结构与功能
Biomedicines. 2020 Aug 31;8(9):319. doi: 10.3390/biomedicines8090319.
利用B细胞受体分析为HIV-1疫苗接种策略提供信息。
Vaccines (Basel). 2020 Jan 1;8(1):13. doi: 10.3390/vaccines8010013.
4
A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.一种用于诱导广泛中和抗体反应的通用 HIV 疫苗设计策略。
Science. 2019 Dec 6;366(6470). doi: 10.1126/science.aax4380. Epub 2019 Oct 31.
5
Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25.人类接种 Pfs25 可引发针对疟疾传播的强效抗体谱系
Nat Commun. 2019 Sep 24;10(1):4328. doi: 10.1038/s41467-019-11980-6.
6
Proteomics Pipeline for Identifying Variant Proteins in Parasites Isolated from Children Presenting with Malaria.寄生虫蛋白质组学分析管道鉴定疟疾患儿样本中的变异蛋白
J Proteome Res. 2019 Nov 1;18(11):3831-3839. doi: 10.1021/acs.jproteome.9b00169. Epub 2019 Oct 8.
7
Antibodies against Plasmodium falciparum malaria at the molecular level.针对疟原虫的抗体在分子水平上。
Nat Rev Immunol. 2019 Dec;19(12):761-775. doi: 10.1038/s41577-019-0209-5. Epub 2019 Aug 28.
8
Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction.疟疾传播阻断疫苗:是时候讨论疫苗引入了。
Trends Parasitol. 2019 Jul;35(7):483-486. doi: 10.1016/j.pt.2019.04.008. Epub 2019 May 29.
9
Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice.慢性寄生虫感染不会损害疟疾传播阻断疫苗 Pfs230D1-EPA/Alhydrogel®在小鼠中的免疫应答。
Vaccine. 2019 Feb 14;37(8):1038-1045. doi: 10.1016/j.vaccine.2019.01.027. Epub 2019 Jan 23.
10
Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A.评估生产工艺变化对重组疫苗载体 ExoProtein A 的理化性质的影响。
Vaccine. 2019 Sep 10;37(38):5762-5769. doi: 10.1016/j.vaccine.2018.09.037. Epub 2018 Sep 24.